Helicos Unveils 'Early Access' Availability of tSMS™ Technologies
News Jan 13, 2006
Helicos BioSciences has announced that it would begin partnering with a selected group of experimental researchers, providing access to its True Single Molecule Sequencing (tSMS™) technologies and techniques in support of research projects.
Helicos' "Early Access" partners may publish their findings from utilizing tSMS™ technologies, as well as present at scientific conferences.
Stanley N. Lapidus, President and CEO of Helicos BioSciences, said, "We are very proud to begin providing access to applications in tSMS™ to a small group of innovative research partners."
"This marks the first time in history that tSMS™ based applications will be open to the experimental community."
He added, "Our intention is to work closely with top researchers and thought leaders to demonstrate the full advantages of leveraging tSMS™ in unlocking experimental possibilities that were inconceivable up to now."
"We look forward to very intriguing and compelling results from these collaborations."
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE